Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 31 to 45 of 556 results for compare

  1. Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin  and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide.

    diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the...

    Research recommendation
    Published
    13 August 2021

  2. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

    Evidence summary
    Published
    10 August 2021

  3. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA512

  4. Further research in people who could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with conventional pacemakers. Follow-up should be for at least 5 years and outcomes should include adverse events, symptom relief, quality of life and device durability in the long-term.

    pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with conventional pacemakers....

    Research recommendation
    Published
    12 December 2018

  5. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    type of treatment: what it involves, the risks and benefits, and how they compare to each other. To help you understand the...

  6. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA663

  7. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA787

  8. Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

    Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1013

  9. LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)

    NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands

    Medtech innovation briefing
    Published
    21 April 2015

  10. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    type of treatment: what it involves, the risks and benefits, and how they compare to each other. To help you understand the...

  11. Long-term complications of spondyloarthritis:- What is the incidence of long-term complications, in particular osteoporosis, cardiovascular disease (CVD) and metabolic syndrome, in people with spondyloarthritis, and how does this compare with the general population? Are any specific spondyloarthritis features or risk factors associated with the incidence and outcomes of these complications?

    metabolic syndrome, in people with spondyloarthritis, and how does this compare with the general population? Are any specific...

    Research recommendation
    Published
    4 May 2017

  12. How effective and cost effective are different types of exercise referral scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome. Compare exercise referral schemes that vary by: - setting – for example, home-based, gym-based, community-based or outdoors - intensity and duration – for example, a 12-week scheme involving 1 session a week, or a 6-week scheme involving 4 1-hour sessions per week - the techniques used, for example, some use additional 'supportive' techniques such as 'motivational interviewing' and education sessions - the target group, for example, people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or socioeconomic status - other scheme characteristics including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it is commissioned and delivered by an NHS, non-NHS or community-based organisation.

    scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome....

    Research recommendation
    Published
    9 June 2015

  13. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA500

  14. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    24 June 2020
    View recommendations

    Sections for MTG49

  15. Upadacitinib for treating severe rheumatoid arthritis (TA665)

    Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA665